{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:26:53Z","timestamp":1789349213124,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.jbspin.2012.12.002","type":"journal-article","created":{"date-parts":[[2013,6,22]],"date-time":"2013-06-22T00:30:21Z","timestamp":1371861021000},"page":"358-362","source":"Crossref","is-referenced-by-count":25,"title":["Vascular effects of nonsteroidal antiinflammatory drugs"],"prefix":"10.1016","volume":"80","author":[{"given":"Martin","family":"Soubrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Tatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Lahaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Dubost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2012.12.002_bib0005","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archinternmed.2011.626","article-title":"Aspirin therapy in primary prevention: comment on \u201ceffect of aspirin on vascular and nonvascular outcomes\u201d","volume":"172","author":"Mora","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0015","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0020","doi-asserted-by":"crossref","first-page":"17597","DOI":"10.1073\/pnas.1209192109","article-title":"Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system","volume":"109","author":"Kirkby","year":"2012","journal-title":"PNAS"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0025","doi-asserted-by":"crossref","first-page":"c7086","DOI":"10.1136\/bmj.c7086","article-title":"Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis","volume":"342","author":"Trelle","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0030","doi-asserted-by":"crossref","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0035","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1161\/CIRCULATIONAHA.110.004671","article-title":"Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study","volume":"123","author":"Schjerning Olsen","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0040","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.112.112607","article-title":"Long-term cardiovascular risk of unsaid use according to time passed after first-time myocardial infarction: a nationwide cohort study","volume":"126","author":"Olsen","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0045","doi-asserted-by":"crossref","first-page":"d4094","DOI":"10.1136\/bmj.d4094","article-title":"Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care","volume":"343","author":"Rodr\u00edguez","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0050","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. Bon usage des agents antiplaquettaires. 2012 [In French]."},{"key":"10.1016\/j.jbspin.2012.12.002_bib0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archinternmed.2011.628","article-title":"Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials","volume":"172","author":"Seshasai","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0060","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-150-6-200903170-00009","article-title":"Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the US Preventive Services Task Force","volume":"150","author":"Wolff","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0070","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"Charlot","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0075","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Castella-Lawson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0195","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-012-1370-y","article-title":"Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study","volume":"69","author":"Meek","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0085","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0090","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/bmj.327.7427.1322","article-title":"Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study","volume":"327","author":"Curtis","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0095","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0100","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(08)61490-7","article-title":"Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial","volume":"372","author":"Baron","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0105","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.106.636746","article-title":"APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas","volume":"114","author":"Solomon","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0110","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/CRD.0b013e31821ddcf4","article-title":"The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients","volume":"19","author":"Snowden","year":"2011","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0115","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1097\/HJH.0b013e3283310dc9","article-title":"Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis","volume":"27","author":"Chan","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0120","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2011.200087","article-title":"Paracetamol and cyclooxygenase inhibition: is there a cause for concern?","volume":"71","author":"Hinz","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0125","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.110.956490","article-title":"Acetaminophen increases blood pressure in patients with coronary artery disease","volume":"122","author":"Sudano","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0130","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/archinte.167.4.394","article-title":"Frequency of analgesic use and risk of hypertension among men","volume":"167","author":"Forman","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0135","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/01.HYP.0000177437.07240.70","article-title":"Non-narcotic analgesic dose and risk of incident hypertension in US women","volume":"46","author":"Forman","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0140","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.105.595793","article-title":"Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events","volume":"113","author":"Chan","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0145","doi-asserted-by":"crossref","unstructured":"Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058\u201373.","DOI":"10.1002\/art.23929"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0150","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0155","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial","volume":"364","author":"Schnitzer","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0165","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/bmj.38232.680567.EB","article-title":"The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review","volume":"329","author":"Hooper","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0170","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MEG.0b013e328349de81","article-title":"Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis","volume":"23","author":"Wang","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0175","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(07)60749-1","article-title":"Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial","volume":"369","author":"Chan","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0180","unstructured":"Afssaps. Rappel des r\u00e8gles de bon usage des AINS. 2006 [In French]."},{"key":"10.1016\/j.jbspin.2012.12.002_bib0185","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/ard.2010.128660","article-title":"The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.12.002_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2011.06.012","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12003132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12003132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T03:21:23Z","timestamp":1539573683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X12003132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1297319X12003132"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2012.12.002","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}